1) Q3 2026 Results Overview - Total company organic sales grew 1.5% YoY, below the guidance of 3% to 5%. - Adjusted EPS was $0.73, a 3% decline YoY and below the guidance range of $0.80 to $0.82. - Results were negatively impacted by a cyber security incident, estimated to have reduced sales growth by 300 basis points and adjusted EPS by $0.07. - Operations resumed fully as of September 8, 2026, after a two-week outage.

2) Segment Performance Insights - Neuromodulation: Sales grew 13% YoY, driven by strong performance in pain management technologies. - Urology: Sales declined 3% YoY, affected by the cyber incident and pricing pressures in China. - Endoscopy: Sales declined 1% YoY, with strong underlying performance but impacted by pricing dynamics in China. - Cardiovascular: Sales grew 2% YoY, with interventional cardiology growing 19% YoY, supported by strong clinical evidence for their drug-coated balloon technology. - EP and Watchman: Sales declined 5% YoY, with Watchman specifically declining 7% in the U.S. due to market dynamics and competition.

3) Challenges and Headwinds - The cyber incident continues to impact operations, with expected ongoing effects of 200 to 300 basis points in Q4. - Intensified pricing pressures in China are anticipated to persist, affecting overall growth. - The EP and Watchman segments are facing significant challenges, with no expected improvement in market dynamics for 2027.

4) Strategic Plans and Future Outlook - For Q4 2026, guidance is for organic revenue declines of -1% to -3% and adjusted EPS of $0.77 to $0.79. - Full-year 2026 adjusted EPS is projected to be between $3.16 and $3.18, reflecting a growth of 3% to 4% YoY. - The company anticipates 2027 will be a trough year, with expectations of stabilization and growth returning in 2028 and beyond, driven by new product launches and strategic investments. - A restructuring program is underway, aiming for over $500 million in savings over three years to enhance operational efficiency.

5) Missing Information and Guidance for 2027 - The transcript lacks specific figures and details on the anticipated impact of the Penumbra acquisition on future earnings. - More clarity on the expected growth from the Penumbra platform and how it will integrate into Boston Scientific's existing portfolio is needed.

Bottom line: Despite current challenges, including the impact of a cyber incident and pricing pressures, Boston Scientific is focused on restructuring and strategic investments to stabilize and return to growth in 2028, making it a potentially attractive opportunity for long-term investors.